Oxbryta Tablet 500 MG Oral
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Hydroxyurea Capsule 500 MG Oral |
Tier 2 |
ST |
Antineoplastics, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Relyvrio Packet 3-1 GM Oral
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Riluzole Tablet 50 MG Oral |
Tier 2 |
|
Central Nervous System, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Selzentry Tablet 25 MG Oral
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Maraviroc Tablet 150 MG Oral |
Tier 4 |
|
Anti-HIV Agents, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Selzentry Tablet 75 MG Oral
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Maraviroc Tablet 150 MG Oral |
Tier 4 |
|
Anti-HIV Agents, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Sprycel Tablet 100 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Dasatinib Tablet 100 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Sprycel Tablet 140 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Dasatinib Tablet 140 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Sprycel Tablet 20 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Dasatinib Tablet 20 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Sprycel Tablet 50 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Dasatinib Tablet 50 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Sprycel Tablet 70 MG Oral
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Dasatinib Tablet 70 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Sprycel Tablet 80 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Dasatinib Tablet 80 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Tazorac Cream 0.05 % External
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Tazarotene Cream 0.05 % External |
Tier 4 |
|
Acne and Rosacea Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Phenytoin Sodium Extended CAPSULE 200 MG ORAL
Type of Change:
Drug removed - Discontinued from marketplace
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Phenytek Capsule 200 MG Oral |
Tier 2 |
|
Sodium Channel Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Phenytoin Sodium Extended CAPSULE 300 MG ORAL
Type of Change:
Drug removed - Discontinued from marketplace
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Phenytek Capsule 300 MG Oral |
Tier 2 |
|
Sodium Channel Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Mesnex Tablet 400 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Mesna Tablet 400 MG Oral |
Tier 5 |
|
Treatment Adjuncts |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Spritam Tablet Disintegrating Soluble 250 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
levETIRAcetam Tablet Disintegrating Soluble 250 MG Oral |
Tier 4 |
PA |
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Isosorbide Mononitrate Tablet 10 MG Oral
Type of Change:
Cost sharing change
Reason Changed:
Cost sharing change
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Isosorbide Mononitrate Tablet 10 MG Oral |
Tier 3 |
|
Vasodilators, Direct-acting Arterial/ Venous |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Isosorbide Mononitrate Tablet 20 MG Oral
Type of Change:
Cost sharing change
Reason Changed:
Cost sharing change
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Isosorbide Mononitrate Tablet 20 MG Oral |
Tier 3 |
|
Vasodilators, Direct-acting Arterial/ Venous |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Purixan Suspension 2000 MG/100ML Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Mercaptopurine Suspension 2000 MG/100ML Oral |
Tier 5 |
|
Antimetabolites |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Brilinta Tablet 90 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Ticagrelor Tablet 90 MG Oral |
Tier 3 |
|
Platelet Modifying Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Libervant Film 10 MG Buccal
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Valtoco 10 MG Dose Liquid 10 MG/0.1ML Nasal |
Tier 4 |
QL |
Gamma-aminobutyric Acid (GABA) Modulating Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Libervant Film 12.5 MG Buccal
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Valtoco 15 MG Dose Liquid Therapy Pack 2 x 7.5 MG/0.1ML Nasal |
Tier 4 |
QL |
Gamma-aminobutyric Acid (GABA) Modulating Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Libervant Film 15 MG Buccal
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Valtoco 15 MG Dose Liquid Therapy Pack 2 x 7.5 MG/0.1ML Nasal |
Tier 4 |
QL |
Gamma-aminobutyric Acid (GABA) Modulating Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Libervant Film 5 MG Buccal
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Valtoco 5 MG Dose Liquid 5 MG/0.1ML Nasal |
Tier 4 |
QL |
Gamma-aminobutyric Acid (GABA) Modulating Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Libervant Film 7.5 MG Buccal
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Valtoco 10 MG Dose Liquid 10 MG/0.1ML Nasal |
Tier 4 |
QL |
Gamma-aminobutyric Acid (GABA) Modulating Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Aptiom Tablet 200 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Eslicarbazepine Acetate Tablet 200 MG Oral |
Tier 4 |
|
Sodium Channel Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Aptiom Tablet 400 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Eslicarbazepine Acetate Tablet 400 MG Oral |
Tier 5 |
|
Sodium Channel Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Aptiom Tablet 600 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Eslicarbazepine Acetate Tablet 600 MG Oral |
Tier 5 |
|
Sodium Channel Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Aptiom Tablet 800 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Eslicarbazepine Acetate Tablet 800 MG Oral |
Tier 5 |
|
Sodium Channel Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Brilinta Tablet 60 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Ticagrelor Tablet 60 MG Oral |
Tier 3 |
|
Platelet Modifying Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Dupixent Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous
Type of Change:
Drug removed - Discontinued from marketplace
Reason Changed:
100 mg dose removed from market. Non-FRF and GPI is inactive.
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Dupixent Solution Auto-Injector 300 MG/2ML Subcutaneous |
Tier 5 |
PA, QL |
Immunological Agents, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Exelderm Cream 1 % External
Type of Change:
Drug removed
Reason Changed:
Removing from formulary as it is being promoted from non-FRF to FRF.
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Ciclopirox Solution 8 % External |
Tier 2 |
|
Topical Anti-infectives |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Lopinavir-Ritonavir Solution 400-100 MG/5ML Oral
Type of Change:
Drug removed
Reason Changed:
Generic demoted to non-FRF. Added brand to ensure access to oral solution
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Kaletra Solution 400-100 MG/5ML Oral |
Tier 4 |
|
Anti-HIV Agents, Protease Inhibitors (PI) |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Retevmo Capsule 80 MG Oral
Type of Change:
Drug removed - Discontinued from marketplace
Reason Changed:
Capsules being discontinued, replacing with tablets
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Retevmo Tablet 80 MG Oral |
Tier 5 |
PA, QL |
Antineoplastics, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Complera Tablet 200-25-300 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Emtricitab-Rilpivir-Tenofov DF Tablet 200-25-300 MG Oral |
Tier 5 |
QL |
Anti-HIV Agents, Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Retevmo Capsule 40 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Retevmo Tablet 40 MG Oral |
Tier 5 |
PA, QL |
Antineoplastics, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Spritam Tablet Disintegrating Soluble 1000 MG Oral
Type of Change:
Drug removed - Discontinued from marketplace
Reason Changed:
Drug strength discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Spritam Tablet Disintegrating Soluble 500 MG Oral |
Tier 4 |
PA |
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Spritam Tablet Disintegrating Soluble 750 MG Oral
Type of Change:
Drug removed - Discontinued from marketplace
Reason Changed:
Drug strength discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Spritam Tablet Disintegrating Soluble 500 MG Oral |
Tier 4 |
PA |
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Tasigna Capsule 150 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Nilotinib HCl Capsule 150 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Tasigna Capsule 200 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Nilotinib HCl Capsule 200 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Tasigna Capsule 50 MG Oral
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Nilotinib HCl Capsule 50 MG Oral |
Tier 5 |
PA, QL |
Molecular Target Inhibitors |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Bronchitol Capsule 40 MG Inhalation
Effective Date:
10/1/2025
Type of Change:
Cost sharing change
Reason Changed:
This was changed to Part D NO
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
1st Tier Unifine Pentips 33G X 4 MM |
Tier 3 |
|
Miscellaneous Therapies (Non-FRF Drugs) |
Pulmozyme Solution 2.5 MG/2.5ML Inhalation |
Tier 5 |
PA |
Cystic Fibrosis Agents |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Entresto Tablet 24-26 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Sacubitril-Valsartan Tablet 24-26 MG Oral |
Tier 2 |
|
Cardiovascular Agents, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Entresto Tablet 49-51 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Sacubitril-Valsartan Tablet 49-51 MG Oral |
Tier 2 |
|
Cardiovascular Agents, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Entresto Tablet 97-103 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Sacubitril-Valsartan Tablet 97-103 MG Oral |
Tier 2 |
|
Cardiovascular Agents, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Fycompa Tablet 10 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Perampanel Tablet 10 MG Oral |
Tier 4 |
|
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Fycompa Tablet 12 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Perampanel Tablet 12 MG Oral |
Tier 4 |
|
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Fycompa Tablet 2 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Perampanel Tablet 2 MG Oral |
Tier 4 |
|
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Fycompa Tablet 4 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Perampanel Tablet 4 MG Oral |
Tier 4 |
|
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Fycompa Tablet 6 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Perampanel Tablet 6 MG Oral |
Tier 4 |
|
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Fycompa Tablet 8 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Perampanel Tablet 8 MG Oral |
Tier 4 |
|
Anticonvulsants, Other |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Ixchiq Solution Reconstituted Intramuscular
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Vimkunya Suspension Prefilled Syringe 40 MCG/0.8ML Intramuscular |
Tier 3 |
|
Vaccines |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Jynarque Tablet 15 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Tolvaptan Tablet 15 MG Oral |
Tier 5 |
PA |
Electrolyte/Mineral/Metal Modifiers |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Jynarque Tablet 30 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Generic therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Tolvaptan Tablet 30 MG Oral |
Tier 5 |
PA |
Electrolyte/Mineral/Metal Modifiers |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Kiprofen Capsule 25 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Removing NDC 73352050410 but maintaining coverage of GPI
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Ketoprofen Capsule 25 MG Oral |
Tier 2 |
|
Nonsteroidal Anti-inflammatory Drugs |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Norethindron-Ethinyl Estrad-Fe Tablet 1-20/1-30/1-35 MG-MCG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Removing NDC 00378730353, but maintaining coverage of GPI
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Tri-Legest Fe TABLET 1-20/1-30/1-35 MG-MCG ORAL |
Tier 2 |
|
Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers) |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
prednisoLONE Sodium Phosphate Tablet Dispersible 10 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Orapred ODT Tablet Dispersible 10 MG Oral |
Tier 4 |
|
Glucocorticoids |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
prednisoLONE Sodium Phosphate Tablet Dispersible 15 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Orapred ODT Tablet Dispersible 15 MG Oral |
Tier 4 |
|
Glucocorticoids |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
prednisoLONE Sodium Phosphate Tablet Dispersible 30 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Therapeutically equivalent product available
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
Orapred ODT Tablet Dispersible 30 MG Oral |
Tier 4 |
|
Glucocorticoids |
* Please reference your Evidence of Coverage for applicable cost-sharing. |
Trecator Tablet 250 MG Oral
Effective Date:
10/1/2025
Type of Change:
Drug removed
Reason Changed:
Drug discontinued from marketplace
Alternative Drugs
Drug |
Tier* |
Drug Restrictions |
Therapy Class |
levoFLOXacin Tablet 750 MG Oral |
Tier 2 |
|
Quinolones |
* Please reference your Evidence of Coverage for applicable cost-sharing. |